Eli Lilly & Company Foundation

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Arda Therapeutics is a biotechnology company founded in 2021 in the San Francisco Bay Area that focuses on addressing chronic diseases and aging by targeting and eliminating pathogenic cells responsible for these conditions. The company utilizes single-cell data to identify specific pathogenic cells and their markers, allowing for the development of precise therapies that exclusively eliminate these harmful cells. This targeted approach aims to eradicate the entire pathological network while preserving healthy cells, thereby enabling effective treatment without adverse effects on the patient's overall cellular health.

Artax Biopharma is a development-stage biopharmaceutical company that is dedicated to the development of new therapies for autoimmune and inflammatory diseases. Its technology provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Ajax Therapeutics is a biotechnology company based in New York City that focuses on developing innovative small molecule therapies for hematologic malignancies. The company utilizes computational chemistry and structure-based technologies to create targeted treatments that address critical cytokine signaling pathways involved in these diseases. By integrating insights from disease mechanisms, genetics, and structural biology with an advanced computational drug discovery platform, Ajax Therapeutics aims to design precise therapeutics that meet significant unmet medical needs for patients suffering from hematologic malignancies.

Zephyr AI is a healthcare technology company focused on transforming drug discovery and precision medicine. By leveraging large, complex datasets and proprietary algorithms, Zephyr AI aims to redefine drug development and streamline clinical trials. The company collaborates with leading health systems, health insurance plans, and biotechnology innovators to enhance the quality of care, improve patient outcomes, and reduce costs. Zephyr AI's innovative approach addresses challenges in clinical decision support and aims to combat various diseases, marking a significant shift in the traditional methods of healthcare delivery.

Trans Solutions Research and Resource Center empowers transgender and gender communities.

Mediar Therapeutics is a pre-clinical stage biotechnology company based in Cambridge, Massachusetts, focused on developing antibody-based therapeutics for the treatment of fibrosis. Founded in 2019, the company aims to provide innovative solutions by targeting key fibrotic mediator proteins that contribute to the development of fibrosis in chronically damaged organs. Through its research and development efforts, Mediar seeks to enable medical practitioners to halt and potentially reverse critical fibrosis and related conditions, addressing a significant unmet need in the field of fibrotic diseases.

Switch Therapeutics is a biotechnology company established in 2020 and located in San Francisco, California. The company focuses on developing innovative RNA interference (RNAi) therapies aimed at transforming the treatment of various diseases, particularly those affecting the central nervous system and other systemic conditions with significant unmet medical needs. By integrating nucleic acid nanotechnology with RNAi science, Switch Therapeutics creates biomarker-gated genetic medicines designed to activate RNA molecules and therapies specifically in targeted cells. This targeted approach aims to enhance the effectiveness of treatments for central nervous system diseases, providing healthcare providers with advanced therapeutic options.

SonoThera is a biotechnology company focused on developing non-viral genetic therapies using ultrasound technology. The company aims to create genetic medicines that address the root causes of human diseases, particularly for conditions that currently have limited or no effective treatments. By leveraging ultrasound-guided nonviral gene therapy, SonoThera seeks to enhance treatment options and improve health outcomes for millions of patients.

Strand Therapeutics is a developer of a biotechnology platform intended to create gene therapies powered by synthetic biology.The company's offerings include immunotherapies to help cells produce target cancer-killing proteins during immunotherapy, enabling patients to improve their body's immune system to fight cancer.

Capstan Therapeutics is a biotechnology company focused on enhancing the therapeutic potential of in vivo RNA-based therapies. It develops proprietary targeted delivery systems, including targeted lipid nanoparticles, to improve the efficacy and control of dosage in engineered cell therapies. This innovative platform aims to address a variety of diseases, particularly in the fields of oncology, fibrosis, and inflammation, where there are significant unmet clinical needs. By advancing precision in vivo cell engineering, Capstan Therapeutics seeks to create transformative therapeutics that can offer new solutions for patients facing these challenging conditions.

Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein post-translational modifications, going beyond degradation to restore protein function, repair signaling, and amplify endogenous disease-fighting mechanisms. Photys was co-founded by the Broad Institute’s leading bifunctional chemist, Amit Choudhary, and the Longwood Fund, alongside a scientific advisory board comprised of distinguished scientists and drug developers – MIT’s Angela Koehler, Salk’s Tony Hunter, Berkeley’s Dan Nomura, MPM’s Wendy Young, and Dana Farber’s Eric Fischer.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Fountain Therapeutics, Inc. is a biotechnology company focused on developing treatments for age-related diseases. Founded in 2018 and based in San Francisco, California, the company aims to create a future where individuals live healthier for longer. It employs a transformative cellular model that mimics the complex characteristics of aging within a laboratory setting. By integrating this model with advanced artificial intelligence and computer vision, Fountain Therapeutics seeks to establish an innovative platform for identifying novel therapeutic targets. This approach is designed to facilitate the development of effective treatments for diseases associated with aging, ultimately aiming to reverse cellular aging and improve health outcomes.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company focuses on developing cell-permeable macrocyclic peptide therapeutics by employing proprietary computational design algorithms and innovative synthetic chemistry. Circle Pharma utilizes an iterative design process that leverages large virtual libraries of conformationally diverse macrocycle scaffolds, which are selected for their inherent permeability. This approach allows the company to create first-in-class macrocycle therapies that can be administered through multiple routes, including oral delivery. The therapeutics target challenging clinical issues, particularly intracellular protein-protein interactions that are significant contributors to cancer, thereby addressing unmet medical needs and enhancing the capabilities of healthcare professionals in their treatment efforts.

Amphista Therapeutics Limited is a biopharmaceutical company based in Motherwell, United Kingdom, established in 2017. The company specializes in targeted protein degradation technology to develop innovative cancer therapeutics. Amphista's approach focuses on harnessing the body's natural processes to selectively and efficiently degrade disease-causing proteins, aiming to create first-in-class treatments. By advancing novel methodologies in targeted protein degradation, Amphista seeks to improve therapeutic efficacy and modulate protein abundance linked to disease progression, ultimately enhancing patient outcomes in oncology.

Indianapolis Cultural Trail operates as a 501c3 nonprofit organization that engages in urban trails and linear parks and is committed to a sustainable funding model that ensures accessible connections for future generations.

Leap Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing targeted and immuno-oncology therapies for cancer treatment. Founded in 2011, the company primarily focuses on acquiring and advancing therapies that inhibit tumor-promoting pathways and activate the immune system against cancer cells. Its lead program, DKN-01, is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1), currently undergoing clinical trials for various cancers, including esophagogastric, gynecologic, and colorectal cancers. Additionally, Leap Therapeutics is developing FL-301, which targets Claudin18.2-expressing cells, along with two preclinical antibody programs, FL-302 and FL-501, aimed at creating transformative cancer treatments.

MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, that specializes in the discovery and development of antibody-based therapeutics for cancer treatment. The company's portfolio includes several investigational products, such as Margetuximab, a monoclonal antibody in Phase III trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other candidates in development include MGA012 and MGD013, both targeting PD-1, as well as MGD019, which targets multiple immune checkpoints. MacroGenics is also advancing MGC018, an antibody-drug conjugate targeting B7-H3, and MGD014, a DART molecule designed for HIV-infected cells. The company has formed strategic collaborations with several organizations to enhance its research and development efforts. Founded in 2000, MacroGenics is committed to innovating immunotherapeutics for cancer and other related diseases.